Ib Acquisition CORP Form 4 insider transactions

GNQ Insilico has entered a global marketing agreement with IBM to deploy its causal AI drug simulation and digital twin platforms.

AQR Capital Management entities reported the sale of common stock in IB Acquisition Corp., reducing their beneficial ownership.

AQR Capital Management Holdings and affiliates reported the sale of 4,619 shares of IB Acquisition Corp. common stock at $10.75 per share.

GNQ Insilico Inc. has entered a two-year joint initiative and marketing agreement with a Fortune 100 global technology company to advance AI-driven drug discovery and precision medicine solutions.

GNQ Insilico Inc., an AI-powered drug development company, will go public through a business combination with IB Acquisition Corp. (NASDAQ: IBAC), valuing GNQ at US$500 million.

AQR Capital Management Holdings and its affiliates sold 195,806 shares of IB Acquisition Corp. common stock for $10.44 per share.

AQR Capital Management entities sold a total of 4,490 shares of IB Acquisition Corp. common stock at $10.50 per share on October 2, 2025.

AQR Capital Management Holdings and its affiliates reported the sale of common stock in IB Acquisition Corp. on October 1, 2025, reducing their beneficial ownership.

AQR Capital Management Holdings and its affiliates reported the sale of common stock in IB Acquisition Corp. on September 30, 2025, reducing their beneficial ownership.

AQR Capital Management entities reported the sale of common stock in IB Acquisition Corp. on September 29, 2025, reducing their beneficial ownership.